1 results match your criteria: "UMR-S970 - Paris Cardiovacasular Research Center (PARCC); Université de Paris Cité[Affiliation]"

Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.

Ann Hematol

November 2022

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou; INSERM, UMR-S970 - Paris Cardiovacasular Research Center (PARCC); Université de Paris Cité, Paris, France.

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder due to the presence of neutralizing autoantibodies directed against the coagulation factor VIII (FVIII). The reference method to detect and quantify anti-FVIII antibodies is the Bethesda assay (BA), but it presents some limitations such as a lack of sensitivity for low titers of inhibitor and the need for experienced laboratory. A commercially available ELISA detecting anti-FVIII antibodies has demonstrated excellent sensitivity and specificity.

View Article and Find Full Text PDF